Unique Presentation Identifier:
5
Program Type
Honors
Faculty Advisor
Dr. Bindu Subhadra
Document Type
Poster
Location
Face-to-face
Start Date
9-4-2026 1:00 PM
End Date
9-4-2026 3:00 PM
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a great advancement in the field of oncology, offering a targeted and adaptable cancer treatment. Traditional therapies, including surgery, chemotherapy, and radiation often have limitations, such as relapse and resistance, highlighting the need for more precise therapeutic options. CAR-T therapy addresses many of these challenges through engineering a patient’s own T-cells to recognize and destroy cancerous cells with specificity and long-lasting immune activity. Since being approved by the FDA in 2017, CAR-T therapy has shown success in treating hematologic malignancies, demonstrating high remission rates in patients with previously limited options. Despite this, its clinical use is limited due to off-target toxicities, high manufacturing costs, and reduced effectiveness in solid tumors. Ongoing research is focused on optimizing CAR design, improving safety, and expanding clinical applications to a wider range of cancers. This review focuses on exploring the mechanism, applications, and efficacy of CAR-T cell therapy. In addition, the adverse effects, strategies to mitigate toxicity, and future directions are discussed.
Recommended Citation
Epperson, Mackenzie R., "CAR-T Cell Therapy – A Revolutionizing Cancer Treatment Through Precision Immunotherapy" (2026). ATU Scholars Symposium. 37.
https://orc.library.atu.edu/atu_rs/2026/2026/37
CAR-T Cell Therapy – A Revolutionizing Cancer Treatment Through Precision Immunotherapy
Face-to-face
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a great advancement in the field of oncology, offering a targeted and adaptable cancer treatment. Traditional therapies, including surgery, chemotherapy, and radiation often have limitations, such as relapse and resistance, highlighting the need for more precise therapeutic options. CAR-T therapy addresses many of these challenges through engineering a patient’s own T-cells to recognize and destroy cancerous cells with specificity and long-lasting immune activity. Since being approved by the FDA in 2017, CAR-T therapy has shown success in treating hematologic malignancies, demonstrating high remission rates in patients with previously limited options. Despite this, its clinical use is limited due to off-target toxicities, high manufacturing costs, and reduced effectiveness in solid tumors. Ongoing research is focused on optimizing CAR design, improving safety, and expanding clinical applications to a wider range of cancers. This review focuses on exploring the mechanism, applications, and efficacy of CAR-T cell therapy. In addition, the adverse effects, strategies to mitigate toxicity, and future directions are discussed.